MX2022012110A - Sistemas crispr clase ii tipo ii. - Google Patents
Sistemas crispr clase ii tipo ii.Info
- Publication number
- MX2022012110A MX2022012110A MX2022012110A MX2022012110A MX2022012110A MX 2022012110 A MX2022012110 A MX 2022012110A MX 2022012110 A MX2022012110 A MX 2022012110A MX 2022012110 A MX2022012110 A MX 2022012110A MX 2022012110 A MX2022012110 A MX 2022012110A
- Authority
- MX
- Mexico
- Prior art keywords
- class
- type
- crispr systems
- enzymes
- crispr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Confectionery (AREA)
- Saccharide Compounds (AREA)
- Seasonings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063003159P | 2020-03-31 | 2020-03-31 | |
| US202063116149P | 2020-11-19 | 2020-11-19 | |
| PCT/US2021/024945 WO2021202568A1 (en) | 2020-03-31 | 2021-03-30 | Class ii, type ii crispr systems |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022012110A true MX2022012110A (es) | 2022-10-18 |
Family
ID=77929138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022012110A MX2022012110A (es) | 2020-03-31 | 2021-03-30 | Sistemas crispr clase ii tipo ii. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11946039B2 (https=) |
| EP (2) | EP4632066A3 (https=) |
| JP (2) | JP7546689B2 (https=) |
| KR (2) | KR102794727B1 (https=) |
| CN (1) | CN116096877B (https=) |
| AU (1) | AU2021248800A1 (https=) |
| CA (1) | CA3177051A1 (https=) |
| ES (1) | ES3055163T3 (https=) |
| GB (1) | GB2608292B (https=) |
| MX (1) | MX2022012110A (https=) |
| WO (1) | WO2021202568A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015330699B2 (en) | 2014-10-10 | 2021-12-02 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| US20220298494A1 (en) * | 2019-02-14 | 2022-09-22 | Metagenomi Ip Technologies, Llc | Enzymes with ruvc domains |
| US10913941B2 (en) | 2019-02-14 | 2021-02-09 | Metagenomi Ip Technologies, Llc | Enzymes with RuvC domains |
| WO2021146641A1 (en) * | 2020-01-17 | 2021-07-22 | The Broad Institute, Inc. | Small type ii-d cas proteins and methods of use thereof |
| WO2021202568A1 (en) | 2020-03-31 | 2021-10-07 | Metagenomi Ip Technologies, Llc | Class ii, type ii crispr systems |
| JP2023540797A (ja) * | 2020-09-11 | 2023-09-26 | メタゲノミ，インコーポレイテッド | 塩基編集酵素 |
| AU2022335499A1 (en) | 2021-08-27 | 2024-02-22 | Metagenomi Therapeutics, Inc. | Enzymes with ruvc domains |
| WO2023081855A1 (en) | 2021-11-05 | 2023-05-11 | Metagenomi, Inc. | Base editing enzymes |
| EP4437095A1 (en) * | 2021-11-24 | 2024-10-02 | Metagenomi, Inc. | Endonuclease systems |
| AU2022396533A1 (en) | 2021-11-24 | 2024-05-02 | Metagenomi Therapeutics, Inc. | Endonuclease systems |
| ES2970263B2 (es) * | 2022-10-21 | 2024-10-11 | Univ Alicante | PROTEINA ENDONUCLEASA Cas9 Y SISTEMA CRISPR-Cas ASOCIADO |
| AU2024236558A1 (en) | 2023-03-15 | 2025-10-09 | Renagade Therapeutics Management Inc. | Delivery of gene editing systems and methods of use thereof |
| WO2024206759A1 (en) * | 2023-03-31 | 2024-10-03 | Arbor Biotechnologies, Inc. | Crispr nuclease polypeptides and gene editing systems comprising such |
| CN121241133A (zh) * | 2023-03-31 | 2025-12-30 | 阿伯生物技术公司 | Crispr核酸酶多肽和包含此类crispr核酸酶多肽的基因编辑系统 |
| WO2024206825A2 (en) * | 2023-03-31 | 2024-10-03 | Aera Therapeutics, Inc. | Modified iscb nucleases, modified guide rnas, and uses thereof |
| WO2024233366A2 (en) * | 2023-05-05 | 2024-11-14 | Aera Therapeutics, Inc. | Modified cas9-iid nucleases and uses thereof |
| EP4716752A2 (en) * | 2023-05-23 | 2026-04-01 | Metagenomi, Inc. | Endonuclease systems |
| WO2025007044A1 (en) * | 2023-06-28 | 2025-01-02 | The University Of Chicago | Methods and compositions comprising iscb variants |
| AU2024335327A1 (en) | 2023-09-01 | 2026-03-26 | Renagade Therapeutics Management Inc. | Gene editing systems, compositions, and methods for treatment of vexas syndrome |
| WO2025054425A1 (en) * | 2023-09-08 | 2025-03-13 | Arbor Biotechnologies, Inc. | Reverse transcription-mediated gene editing systems and uses thereof |
| WO2025174765A1 (en) | 2024-02-12 | 2025-08-21 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6291438B1 (en) | 1993-02-24 | 2001-09-18 | Jui H. Wang | Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use |
| US5858988A (en) | 1993-02-24 | 1999-01-12 | Wang; Jui H. | Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use |
| US9637739B2 (en) * | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
| PL3360964T3 (pl) | 2012-12-06 | 2020-03-31 | Sigma-Aldrich Co. Llc | Modyfikacja i regulacja genomu oparta na crispr |
| WO2014093655A2 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| CN113355357B (zh) | 2012-12-12 | 2024-12-03 | 布罗德研究所有限公司 | 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化 |
| WO2015066119A1 (en) | 2013-10-30 | 2015-05-07 | North Carolina State University | Compositions and methods related to a type-ii crispr-cas system in lactobacillus buchneri |
| WO2015089364A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Crystal structure of a crispr-cas system, and uses thereof |
| EP4464338A3 (en) | 2014-11-07 | 2025-02-12 | Editas Medicine, Inc. | Systems for improving crispr/cas-mediated genome-editing |
| KR20230156800A (ko) | 2015-03-03 | 2023-11-14 | 더 제너럴 하스피탈 코포레이션 | 변경된 PAM 특이성을 갖는 조작된 CRISPR-Cas9 뉴클레아제 |
| AU2016263026A1 (en) | 2015-05-15 | 2017-11-09 | Pioneer Hi-Bred International, Inc. | Guide RNA/Cas endonuclease systems |
| WO2016196655A1 (en) | 2015-06-03 | 2016-12-08 | The Regents Of The University Of California | Cas9 variants and methods of use thereof |
| US20160362667A1 (en) | 2015-06-10 | 2016-12-15 | Caribou Biosciences, Inc. | CRISPR-Cas Compositions and Methods |
| TWI906646B (zh) | 2015-06-18 | 2025-12-01 | 美商博得學院股份有限公司 | 降低脫靶效應的ｃｒｉｓｐｒ酶突變 |
| EP3426780A1 (en) | 2016-03-11 | 2019-01-16 | Pioneer Hi-Bred International, Inc. | Novel cas9 systems and methods of use |
| EP3500967A1 (en) | 2016-08-17 | 2019-06-26 | The Broad Institute, Inc. | Methods for identifying class 2 crispr-cas systems |
| BR112019006388A2 (pt) * | 2016-09-30 | 2019-06-25 | Univ California | enzimas modificadoras de ácido nucleico guiadas por rna e métodos de uso das mesmas |
| SG10201913505WA (en) | 2016-10-17 | 2020-02-27 | Univ Nanyang Tech | Truncated crispr-cas proteins for dna targeting |
| SG11201906297QA (en) | 2017-03-24 | 2019-10-30 | Curevac Ag | Nucleic acids encoding crispr-associated proteins and uses thereof |
| EP3617311B1 (en) | 2017-03-30 | 2024-11-20 | Kyoto University | Method for inducing exon skipping by genome editing |
| EP3625338A4 (en) | 2017-05-19 | 2021-01-20 | Tsinghua University | CONSTRUCTION OF A MINIMAL SACAS9-CRISPR / CAS SYSTEM FOR GENEDITATION AND TRANSCRIPTION REGULATION, OPTIMIZED BY EXTENDED GUIDE-RNA |
| US10011849B1 (en) | 2017-06-23 | 2018-07-03 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| US9982279B1 (en) | 2017-06-23 | 2018-05-29 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| KR102465067B1 (ko) * | 2018-02-15 | 2022-11-10 | 시그마-알드리치 컴퍼니., 엘엘씨 | 진핵 게놈 변형을 위한 조작된 cas9 시스템 |
| WO2019165168A1 (en) | 2018-02-23 | 2019-08-29 | Pioneer Hi-Bred International, Inc. | Novel cas9 orthologs |
| WO2020055941A1 (en) | 2018-09-13 | 2020-03-19 | Excision Biotherapeutics, Inc. | Compositions and methods for excision with single grna |
| US20220298494A1 (en) | 2019-02-14 | 2022-09-22 | Metagenomi Ip Technologies, Llc | Enzymes with ruvc domains |
| US20220220460A1 (en) | 2019-02-14 | 2022-07-14 | Metagenomi Ip Technologies, Llc | Enzymes with ruvc domains |
| WO2021226363A1 (en) | 2020-05-08 | 2021-11-11 | Metagenomi Ip Technologies, Llc | Enzymes with ruvc domains |
| US10913941B2 (en) | 2019-02-14 | 2021-02-09 | Metagenomi Ip Technologies, Llc | Enzymes with RuvC domains |
| CA3241703C (en) * | 2019-02-14 | 2026-02-24 | Metagenomi Therapeutics, Inc. | Enzymes with ruvc domains |
| US20220235340A1 (en) | 2019-05-20 | 2022-07-28 | The Broad Institute, Inc. | Novel crispr-cas systems and uses thereof |
| WO2021097118A1 (en) * | 2019-11-12 | 2021-05-20 | The Broad Institute, Inc. | Small type ii cas proteins and methods of use thereof |
| WO2021202568A1 (en) | 2020-03-31 | 2021-10-07 | Metagenomi Ip Technologies, Llc | Class ii, type ii crispr systems |
| WO2021202559A1 (en) * | 2020-03-31 | 2021-10-07 | Metagenomi Ip Technologies, Llc | Class ii, type ii crispr systems |
| EP4165177A4 (en) | 2020-05-08 | 2024-08-28 | Metagenomi, Inc. | ENZYMES WITH RUVC DOMAINS |
| JP2023540797A (ja) * | 2020-09-11 | 2023-09-26 | メタゲノミ，インコーポレイテッド | 塩基編集酵素 |
| CN116867897A (zh) * | 2020-09-11 | 2023-10-10 | 宏基因组学公司 | 碱基编辑酶 |
| JP2023546671A (ja) | 2020-10-23 | 2023-11-07 | ザ・ブロード・インスティテュート・インコーポレイテッド | 再プログラム可能なｉｓｃｂヌクレアーゼ及びその使用 |
-
2021
- 2021-03-30 WO PCT/US2021/024945 patent/WO2021202568A1/en not_active Ceased
- 2021-03-30 JP JP2022559475A patent/JP7546689B2/ja active Active
- 2021-03-30 KR KR1020227037087A patent/KR102794727B1/ko active Active
- 2021-03-30 AU AU2021248800A patent/AU2021248800A1/en active Pending
- 2021-03-30 EP EP25194658.8A patent/EP4632066A3/en active Pending
- 2021-03-30 CA CA3177051A patent/CA3177051A1/en active Pending
- 2021-03-30 MX MX2022012110A patent/MX2022012110A/es unknown
- 2021-03-30 KR KR1020257011372A patent/KR20250051161A/ko active Pending
- 2021-03-30 EP EP21779798.4A patent/EP4127156B1/en active Active
- 2021-03-30 GB GB2211839.2A patent/GB2608292B/en active Active
- 2021-03-30 ES ES21779798T patent/ES3055163T3/es active Active
- 2021-03-30 CN CN202180039435.5A patent/CN116096877B/zh active Active
-
2022
- 2022-07-05 US US17/857,923 patent/US11946039B2/en active Active
-
2024
- 2024-02-07 US US18/435,779 patent/US20240309356A1/en active Pending
- 2024-08-26 JP JP2024144487A patent/JP7785139B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR102794727B1 (ko) | 2025-04-11 |
| JP7546689B2 (ja) | 2024-09-06 |
| KR20220161383A (ko) | 2022-12-06 |
| CN116096877A (zh) | 2023-05-09 |
| US11946039B2 (en) | 2024-04-02 |
| KR20250051161A (ko) | 2025-04-16 |
| EP4127156B1 (en) | 2025-09-10 |
| ES3055163T3 (en) | 2026-02-10 |
| JP7785139B2 (ja) | 2025-12-12 |
| CN116096877B (zh) | 2026-04-28 |
| WO2021202568A1 (en) | 2021-10-07 |
| US20230051396A1 (en) | 2023-02-16 |
| JP2024178181A (ja) | 2024-12-24 |
| EP4632066A2 (en) | 2025-10-15 |
| AU2021248800A1 (en) | 2022-10-13 |
| GB202211839D0 (en) | 2022-09-28 |
| EP4127156C0 (en) | 2025-09-10 |
| GB2608292B (en) | 2024-02-14 |
| EP4127156A4 (en) | 2024-03-27 |
| GB2608292A (en) | 2022-12-28 |
| EP4127156A1 (en) | 2023-02-08 |
| CA3177051A1 (en) | 2021-10-07 |
| JP2023519953A (ja) | 2023-05-15 |
| EP4632066A3 (en) | 2025-12-24 |
| US20240309356A1 (en) | 2024-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022012110A (es) | Sistemas crispr clase ii tipo ii. | |
| GB2605340A8 (en) | Base editing enzymes | |
| WO2019014395A8 (en) | GENERATION OF WATER-SOLUBLE CANNABINOID COMPOUNDS IN PLANT CELL SUSPENSION YEAST AND CROPS AND MATERIAL COMPOSITIONS | |
| MX2022014067A (es) | Enzimas con dominios ruvc. | |
| TN2023000250A1 (en) | Inhibiting ubiquitin-specific protease 1 (usp1) | |
| WO2021127283A3 (en) | Irak degraders and uses thereof | |
| MX2022011039A (es) | Sistemas crispr clase ii tipo v. | |
| WO2020236972A3 (en) | Non-classi engineered crispr-cas polynucleotide targeting system | |
| WO2020243415A3 (en) | Tead inhibitors and uses thereof | |
| WO2018175636A3 (en) | Compositions and methods for immunooncology | |
| PH12021553018A1 (en) | New egfr inhibitors | |
| EP4212622A3 (en) | Bacillus gibsonii-clade serine proteases | |
| WO2019117673A3 (ko) | 신규 폴리펩타이드 및 이를 이용한 imp 생산방법 | |
| MY189774A (en) | Atropine-containing aqueous composition | |
| WO2020003006A3 (en) | Compositions and methods for genomic editing by insertion of donor polynucleotides | |
| ZA202309516B (en) | Anti-ccr8 antibodies | |
| EP4700161A3 (en) | Direct-to-library methods, systems, and compositions | |
| WO2018146557A3 (en) | Long double-stranded rna for rna interference | |
| WO2022232638A3 (en) | Enzymes with ruvc domains | |
| WO2023081762A3 (en) | Serine recombinases | |
| MX2022014126A (es) | Moduladores de enpp1 y usos de los mismos. | |
| MY197889A (en) | Microorganism producing l-amino acid and method for producing l-amino acid using the same | |
| EP4696364A3 (en) | A system for planning and/or providing neuromodulation | |
| EP4685235A3 (en) | Proteases for beer haze reduction | |
| MX2023014628A (es) | Vectores de expresion, vectores libres de secuencias bacterianas y metodos para fabricar y usar los mismos. |